[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-401064-105":59,"doc-detail-401064-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","oral-pre-exposure-prophylaxis-prep-frequently-asked-questions","Oral pre-exposure prophylaxis (PrEP) - Frequently asked questions","","Frequently asked questions explain oral pre-exposure prophylaxis (PrEP) as a daily, fixed-dose combination of tenofovir (TDF) and emtricitabine (FTC) to help HIV-negative people prevent HIV before potential exposure. Guidance covers who should be considered, timing to achieve full protection, eligibility limits including kidney function thresholds and acute HIV symptoms, and how decisions are made during pregnancy and breastfeeding. It also outlines monitoring steps, key baseline investigations, safety information, and actions for acute infection or seroconversion.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/oral-pre-exposure-prophylaxis-prep-frequently-asked-questions/401064/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/oral-pre-exposure-prophylaxis-prep-frequently-asked-questions/401064.png","ImageObject",300,407,{"name":92,"@type":93},"AfterMidnight","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-27",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is PrEP and how is it taken?","Question",{"text":112,"@type":113},"PrEP is an effective option for HIV-negative people to prevent contracting HIV before potential exposure. It is taken as a daily fixed-dose combination of tenofovir (TDF) and emtricitabine (FTC).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Who should be considered for PrEP, and what groups are considered high-risk?",{"text":117,"@type":113},"Any person requesting or requiring PrEP should be considered. High-risk groups include men who have sex with men (MSM), sex workers, adolescents and young women and men, migrant workers, pregnant and breastfeeding women, people with more than one sexual partner, people who inject drugs, and those with a recent history of STI(s) or who recognize their own risk; serodiscordant couples are also included when the HIV-positive partner’s viral load is not suppressed.",{"name":119,"@type":110,"acceptedAnswer":120},"When should PrEP be started and what should clients do in the first 7 days?",{"text":121,"@type":113},"When first starting PrEP, it needs to be taken consistently for 7 days to provide full protection. Clients should be advised to avoid having sex or to use condoms during this period.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},401064,1791106168,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":14,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":24,"preview_page_count":4},962090896061,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Oral pre-exposure prophylaxis (PrEP)  \nFrequently asked questions  \nBased on the Updated Guidelines for the provision of oral pre-exposure prophylaxis (PrEP) to persons at substantial risk of HIV infection, published October 2021, National Department of Health, South Africa  \nWhat is PrEP?  \nPre-exposure prophylaxis (PrEP) is an effective option for HIV-negative people to prevent contracting HIV before potential exposure. The HIV-negative person takes a fixed dose combination of two antiretrovirals – tenofovir (TDF) and emtricitabine (FTC)– on a daily basis.  \nWho should be considered for PrEP?  \nAny person requesting or requiring PrEP, even if the healthcare worker does not perceive this person to beat risk.  \nPeople considered to be high-risk for HIV include:  \n• men who have sex with men (MSM)  \n• sex workers  \n• adolescents and young women and men  \n• migrant workers  \n• pregnant and breastfeeding women  \n• people who have more than one sexual partner  \n• people who inject drugs  \n• people with a recent history of STI(s)  \n• people who recognise their own risk and request PrEP  \n• serodiscordant couples, if the HIV-positive partner’s viral load is not suppressed  \nHow long before PrEP is active?  \nWhen first starting PrEP, it needs to be taken consistently for 7 days before it provides its full protection. Clients should be advised to avoid having sex or to use condoms during this period.  \nWho cannot use PrEP?  \n• People who are HIV-positive  \n• People with poor kidney function (Table 1):  \n􀀍 Adults and adolescents ≥ 16 years: eGFR \u003C 50 mL/min  \n* Adolescents ≥ 10 and \u003C 16 years: eGFR \u003C 80 mL/min  \n* Pregnant clients: serum creatinine (sCr) > 85 μmol/L  \nIf the client has symptoms or signs of acute HIV infection, PrEP should be postponed until symptoms subside and a repeat rapid HIV test after 4 weeks remains negative.  \nPrEP in pregnancy and breastfeeding?  \nThe choice to start, continue or discontinue PrEP during pregnancy and breastfeeding, should be made by the client, following a discussion of the risks and benefits with the healthcare provider.  \nThe key message for risk/benefit counselling for pregnant and breastfeeding clients: the benefits of taking PrEP during pregnancy and when breastfeeding for an HIV-negative client, far outweighs the risk of any possible harm to the mother and baby. The WHO recommends that PrEP is safe for use in pregnant or breastfeeding clients at substantial risk of HIV infection.  \nHow are clients on PrEP monitored?  \nRoutine creatinine monitoring is not required in all populations (Table 1) . Monitoring includes HIV testing, hepatitis B surface antigen screen (at baseline), STIsyndromic screening, pregnancy screen and creatinine monitoring/eGFR in some populations (Table 2) . Clients with acute or chronic hepatitis B may need liver function tests done.  \nTable 1: Assessing renal function  \n\n| Age/ pregnant | Measurement used | Acceptable level for PrEP use |\n| --- | --- | --- |\n| ≥ 10 and \u003C 16 years | eGFR using Counahan Barratt formula (below) | > 80 mL/min/1 . 73m2 |\n| ≥ 16 years | eGFR | > 50 mL/min/1 . 73m2 |\n| Pregnant | Serum creatinine | \u003C 85 µmol/L |\n| Criteria for and frequency of eGFR and sCr monitoring |  |  |\n| Age/ pregnant | Co-morbidity | When to do creatinine |\n| \u003C30 Years | None | Not required |\n| ≥ 30 Years | None | Baseline |\n| All (except pregnancy) | Diabetes and/or hypertension | Baseline and annually |\n| Pregnancy | N/A | Baseline, 3 and 6 months |\n\nThe Counahan Barratt formula:  \neGFR (mL/min/1.73 m2) = ~~ ~~Cr~~heig~~eati~~h~~ni~~t~~n~~(c~~e(~~m~~µ~~)~~Xmo~~4~~l~~0~~/L)~~ ~~  \nTable 2: Baseline investigations and monitoring  \n\n| Investigation Action to be taken |  |\n| --- | --- |\n| HIV Test (use algorithm in National HTS guidelines) | If client is HIV-positive, initiate on ART. If client is HIV-negative, screen for PrEP. Repeat HIV test after 1 month of PrEP initiation, then 3-monthly thereafter. |\n| Hepatitis B surface antigen (HBsAg) | If HbsAg negative: start","cbCaimIreIjReIKp","https://ap.wps.com/l/cbCaimIreIjReIKp","pdf",368627,"English","# What is PrEP?\n# Who should be considered for PrEP?\n# How long before PrEP is active?\n# Who cannot use PrEP?\n# PrEP in pregnancy and breastfeeding?\n# How are clients on PrEP monitored?\n# Safety of PrEP\n# What happens if the PrEP user tests HIV-positive?\n# Switching from PEP to PrEP\n# Signs of acute HIV Infection","[{\"question\":\"What is PrEP and how is it taken?\",\"answer\":\"PrEP is an effective option for HIV-negative people to prevent contracting HIV before potential exposure. It is taken as a daily fixed-dose combination of tenofovir (TDF) and emtricitabine (FTC).\"},{\"question\":\"Who should be considered for PrEP, and what groups are considered high-risk?\",\"answer\":\"Any person requesting or requiring PrEP should be considered. High-risk groups include men who have sex with men (MSM), sex workers, adolescents and young women and men, migrant workers, pregnant and breastfeeding women, people with more than one sexual partner, people who inject drugs, and those with a recent history of STI(s) or who recognize their own risk; serodiscordant couples are also included when the HIV-positive partner’s viral load is not suppressed.\"},{\"question\":\"When should PrEP be started and what should clients do in the first 7 days?\",\"answer\":\"When first starting PrEP, it needs to be taken consistently for 7 days to provide full protection. Clients should be advised to avoid having sex or to use condoms during this period.\"}]","Oral pre-exposure prophylaxis (PrEP) - Frequently asked questions | PDF",1790516331]